Incyte Corporation – Product Pipeline Review

Global Markets Direct’s, ‘Incyte Corporation – Product Pipeline Review – 2016’, provides an overview of the Incyte Corporation’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Incyte Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Incyte Corporation

The report provides overview of Incyte Corporation including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Incyte Corporation’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Incyte Corporation’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Incyte Corporation’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Incyte Corporation

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Incyte Corporation’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Incyte Corporation Snapshot 6

Incyte Corporation Overview 6

Key Information 6

Key Facts 6

Incyte Corporation - Research and Development Overview 7

Key Therapeutic Areas 7

Incyte Corporation - Pipeline Review 13

Pipeline Products by Stage of Development 13

Pipeline Products - Monotherapy 14

Pipeline Products - Combination Treatment Modalities 15

Pipeline Products - Partnered Products 16

Partnered Products/Combination Treatment Modalities 17

Pipeline Products - Out-Licensed Products 18

Out-Licensed Products/Combination Treatment Modalities 19

Incyte Corporation - Pipeline Products Glance 20

Incyte Corporation - Clinical Stage Pipeline Products 20

Phase II Products/Combination Treatment Modalities 20

Phase I Products/Combination Treatment Modalities 21

Incyte Corporation - Early Stage Pipeline Products 22

IND/CTA Filed Products/Combination Treatment Modalities 22

Preclinical Products/Combination Treatment Modalities 23

Discovery Products/Combination Treatment Modalities 24

Incyte Corporation - Drug Profiles 25

(INCB-039110 + INCB-040093) 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

epacadostat 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

INCB-40093 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

itacitinib adipate 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

ruxolitinib phosphate 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

INCB-50465 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

INCB-52793 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

INCB-53914 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

INCB-54329 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

INCB-54828 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

INCB-59872 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

SHR-1210 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

INCAGN-1876 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

INCAGN-1949 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

INCB-57643 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Monoclonal Antibody to Inhibit LAG3 for Oncology 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

Monoclonal Antibody to Inhibit TIM3 for Oncology 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Small Molecule for Oncology 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

Small Molecules for Chronic Inflammation 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

Incyte Corporation - Pipeline Analysis 52

Incyte Corporation - Pipeline Products by Target 52

Incyte Corporation - Pipeline Products by Route of Administration 54

Incyte Corporation - Pipeline Products by Molecule Type 55

Incyte Corporation - Pipeline Products by Mechanism of Action 56

Incyte Corporation - Recent Pipeline Updates 58

Incyte Corporation - Dormant Projects 75

Incyte Corporation - Discontinued Pipeline Products 76

Discontinued Pipeline Product Profiles 76

aderbasib 76

INCB-047986 76

itacitinib adipate 76

ruxolitinib phosphate 76

Incyte Corporation - Company Statement 78

Incyte Corporation - Locations And Subsidiaries 82

Head Office 82

Other Locations & Subsidiaries 82

Appendix 83

Methodology 83

Coverage 83

Secondary Research 83

Primary Research 83

Expert Panel Validation 83

Contact Us 83

Disclaimer 84

List of Tables

List of Tables

Incyte Corporation, Key Information 6

Incyte Corporation, Key Facts 6

Incyte Corporation – Pipeline by Indication, 2016 8

Incyte Corporation – Pipeline by Stage of Development, 2016 13

Incyte Corporation – Monotherapy Products in Pipeline, 2016 14

Incyte Corporation – Combination Treatment Modalities in Pipeline, 2016 15

Incyte Corporation – Partnered Products in Pipeline, 2016 16

Incyte Corporation – Partnered Products/ Combination Treatment Modalities, 2016 17

Incyte Corporation – Out-Licensed Products in Pipeline, 2016 18

Incyte Corporation – Out-Licensed Products/ Combination Treatment Modalities, 2016 19

Incyte Corporation – Phase II, 2016 20

Incyte Corporation – Phase I, 2016 21

Incyte Corporation – IND/CTA Filed, 2016 22

Incyte Corporation – Preclinical, 2016 23

Incyte Corporation – Discovery, 2016 24

Incyte Corporation – Pipeline by Target, 2016 53

Incyte Corporation – Pipeline by Route of Administration, 2016 54

Incyte Corporation – Pipeline by Molecule Type, 2016 55

Incyte Corporation – Pipeline Products by Mechanism of Action, 2016 56

Incyte Corporation – Recent Pipeline Updates, 2016 58

Incyte Corporation – Dormant Developmental Projects,2016 75

Incyte Corporation – Discontinued Pipeline Products, 2016 76

Incyte Corporation, Subsidiaries 82

List of Figures

List of Figures

Incyte Corporation – Pipeline by Top 10 Indication, 2016 8

Incyte Corporation – Pipeline by Stage of Development, 2016 13

Incyte Corporation – Monotherapy Products in Pipeline, 2016 14

Incyte Corporation – Combination Treatment Modalities in Pipeline, 2016 15

Incyte Corporation – Partnered Products in Pipeline, 2016 16

Incyte Corporation – Out-Licensed Products in Pipeline, 2016 18

Incyte Corporation – Pipeline by Top 10 Target, 2016 52

Incyte Corporation – Pipeline by Route of Administration, 2016 54

Incyte Corporation – Pipeline by Molecule Type, 2016 55

Incyte Corporation – Pipeline Products by Top 10 Mechanism of Action, 2016 56

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports